

AUG 01, 2023

OPEN ACCESS



DOI:

dx.doi.org/10.17504/protocol s.io.dm6gp3b7dvzp/v1

Protocol Citation: Tae-Un Han, sidranse 2023. In-vitro GCase Activity Assay. protocols.io

https://dx.doi.org/10.17504/p rotocols.io.dm6gp3b7dvzp/v1

License: This is an open access protocol distributed under the terms of the Creative Commons Attribution License. which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working We use this protocol and it's working

Created: Aug 01, 2023

Last Modified: Aug 01, 2023

(1) In-vitro GCase Activity Assay

Tae-Un Han¹, sidranse¹

¹Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, USA.



Tae-Un Han

ABSTRACT

This is version 2 of in-vitro GCase activity assay.

We optimized the assay condition to enhance sensitivity and specificity. Both cell lysates and protein lysates prepared in M-buffer containing protease inhibitor and 0.25% TritonX can use this protocol.

ATTACHMENTS

GCase Activity Assay.pdf

MATERIALS

- Cell lysates and protein lysates prepared in M-buffer containing protease inhibitor and 0.25% TritonX
- 0.2M Na₂HPO₄
- 0.1M citrate
- protease inhibitor tablet (Roche cOmplet mini)
- Triton X-100 solution
- 384 well plate (flat bottom, black)
- 10 mM CBE (5 mg CBE in 3086 ul DMSO)
- DMSO
- aluminum foil
- sodium taurocholate powder
- 1 M 4-Methylumbelliferyl-B-D-glucoside (4-MU-G, 338 mg per 1ml DMF)
- 5 M NaOH
- glycine
- microplate reader

PROTOCOL integer ID:


85785

Keywords: ASAPCRN, GCase, GCase activity



- Dissolve one protease inhibitor tablet (Roche cOmplet mini) in \square 10 mL M-buffer. Triton X-100 solution to \square 10 mL 0.25 % (v/v) (e.g. \square 25 \square 10 mL) and \square 10 mL 0.2 Mass / % volume of sodium taurocholate to make active GCase buffer.
- 3 Set up the desired plate layout in a 384 well plate (flat bottom, black). There should be two sections, as each sample must be prepared and assayed both with and without CBE (CBE: GCase1 inhibitor).
- Prepare [M] 0.8 millimolar (mM) by diluting [M] 10 millimolar (mM) in DMSO with the GCase buffer (GCase buffer:CBE = 92:8).
- 5 Prepare CBE-free carrier solution in the same volume of GCase buffer/DMSO (GCase buffer:DMSO = 92:8).
- Pipette Pipette I lysate diluted with GCase buffer into wells of a 384- well plate. Four replication sets should be run (sample concentration: [M] 0.7 mg/mL ~ [M] 1.2 mg/mL). Protein concentration should be adjusted to be similar between control and experiment groups using GCase buffer.
 - 7 Add Δ 5 μ L 0.8 mM CBE solution to the CBE-positive wells or the same volume of CBE-free carrier solution to the CBE-negative wells.

Cover the plate with aluminum foil and briefly centrifuge. Incubate shaking:



- During incubation, prepare 4-Methylumbelliferyl-B-D-glucoside (4-MU) diluent by diluting 1 M 4-Mu (338 mg per 1ml DMF) with GCase buffer to a final concentration of [M] 2.5 millimolar (mM) (1:400 dilution).
- After the CBE incubation, spin down the plate and add to reach a total volume of \square 30 μ L in each well.
- 11 Cover the plate with aluminum and briefly centrifuge, and Incubate shaking:





- Prepare stop solution by adding NaOH and 1.877 g up to 25 mL in water. Final concentration of glycine is M1 Molarity (M) (pH 10.5)
- After incubation, spin down the plate again and Add

 After incubation, spin down the plate again and Add solution to each well.
- Read the 4-MU fluorescence with a microplate reader (Excitation: 365 nm; Emission: 449 nm; Cutoff: 435nm; 3 reads/well).
- 15 GCase activity in each protein lysate can be calculated as below.

 $\label{lem:concentration:cbe} $$ \operatorname{luorescence:of:CBE:-free:sample \quad fluorescence:of:sample:with:CBE} $$ {\operatorname{luorescence:of:measured:by:BCA}} $$$